BR9713847A - Polipeptìdeo isolado codificado por um gene semelhante a lipase, composição, composição farmacêutica, fragmento antigênico, ácido nucleico isolado, vetor, célula recombinante, anticorpo, célula de hibridoma, processos para preparar um polipeptìdeo, para triar agonistas ou antagonistas de atividade llg, para a hidrólise enzimática de um éster de fosfatidilcolina, e para melhorar o perfil de lipìdeo no soro de um humano ou outro animal tendo um perfil de lipìdeo indesejável, e, camundongo transgênico. - Google Patents

Polipeptìdeo isolado codificado por um gene semelhante a lipase, composição, composição farmacêutica, fragmento antigênico, ácido nucleico isolado, vetor, célula recombinante, anticorpo, célula de hibridoma, processos para preparar um polipeptìdeo, para triar agonistas ou antagonistas de atividade llg, para a hidrólise enzimática de um éster de fosfatidilcolina, e para melhorar o perfil de lipìdeo no soro de um humano ou outro animal tendo um perfil de lipìdeo indesejável, e, camundongo transgênico.

Info

Publication number
BR9713847A
BR9713847A BR9713847-9A BR9713847A BR9713847A BR 9713847 A BR9713847 A BR 9713847A BR 9713847 A BR9713847 A BR 9713847A BR 9713847 A BR9713847 A BR 9713847A
Authority
BR
Brazil
Prior art keywords
lipid profile
composition
processes
lipase
polypeptides
Prior art date
Application number
BR9713847-9A
Other languages
English (en)
Inventor
Michael C Jaye
Kim-Anh Thi Doan
John A Krawiec
Kevin J Lynch
Dilip V Amin
Victoria J South
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of BR9713847A publication Critical patent/BR9713847A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"POLIPEPTìDEO ISOLADO CODIFICADO POR UM GENE SEMELHANTE A LIPASE, COMPOSIçãO, COMPOSIçãO FARMACêUTICA, FRAGMENTO ANTIGêNICO, áCIDO NUCLEICO ISOLADO, VETOR, CéLULA RECOMBINANTE, ANTICORPO, CéLULA DE HIBRIDOMA, PROCESSOS PARA PREPARAR UM POLIPEPTìDEO, PARA TRIAR AGONISTAS OU ANTAGONISTAS DE ATIVIDADE LLG, PARA A HIDRóLISE ENZIMáTICA DE UM éSTER DE FOSFATIDILCOLINA, E PARA MELHORAR O PERFIL DE LIPìDEO NO SORO DE UM HUMANO OU OUTRO ANIMAL TENDO UM PERFIL DE LIPìDEOS INDESEJáVEL, E, CAMUNDONGO TRANSGêNICO". Polipeptídeos semelhantes a lipase de lipoproteína, ácidos nucleicos codificando referidos polipeptídeos, seq³ências anti-sentido, e anticorpos para referidos polipeptídeos são descritos. Também são descritos processos para a preparação de referidos polipeptídeos em um sistema recombinante e para o uso dos referidos polipeptídeos para triar agonistas ou antagonistas de referidos polipeptídeos. Também são descritos processos e composições para o tratamento de distúrbios de metabolismo de lipídeos.
BR9713847-9A 1996-12-06 1997-12-05 Polipeptìdeo isolado codificado por um gene semelhante a lipase, composição, composição farmacêutica, fragmento antigênico, ácido nucleico isolado, vetor, célula recombinante, anticorpo, célula de hibridoma, processos para preparar um polipeptìdeo, para triar agonistas ou antagonistas de atividade llg, para a hidrólise enzimática de um éster de fosfatidilcolina, e para melhorar o perfil de lipìdeo no soro de um humano ou outro animal tendo um perfil de lipìdeo indesejável, e, camundongo transgênico. BR9713847A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3278396P 1996-12-06 1996-12-06
US3225496P 1996-12-06 1996-12-06
PCT/US1997/022331 WO1998024888A2 (en) 1996-12-06 1997-12-05 Polypeptides encoded by a human lipase-like gene, compositions and methods

Publications (1)

Publication Number Publication Date
BR9713847A true BR9713847A (pt) 2000-02-29

Family

ID=26708180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713847-9A BR9713847A (pt) 1996-12-06 1997-12-05 Polipeptìdeo isolado codificado por um gene semelhante a lipase, composição, composição farmacêutica, fragmento antigênico, ácido nucleico isolado, vetor, célula recombinante, anticorpo, célula de hibridoma, processos para preparar um polipeptìdeo, para triar agonistas ou antagonistas de atividade llg, para a hidrólise enzimática de um éster de fosfatidilcolina, e para melhorar o perfil de lipìdeo no soro de um humano ou outro animal tendo um perfil de lipìdeo indesejável, e, camundongo transgênico.

Country Status (22)

Country Link
US (4) US6395530B1 (pt)
EP (1) EP0948609B1 (pt)
JP (2) JP4615634B2 (pt)
KR (1) KR100516561B1 (pt)
CN (2) CN1167793C (pt)
AP (1) AP1313A (pt)
AT (1) ATE291080T1 (pt)
AU (1) AU750891B2 (pt)
BG (1) BG64798B1 (pt)
BR (1) BR9713847A (pt)
CA (1) CA2273823C (pt)
CZ (1) CZ299055B6 (pt)
DE (2) DE948609T1 (pt)
EA (1) EA003293B1 (pt)
ES (1) ES2239367T3 (pt)
HK (2) HK1024929A1 (pt)
IL (2) IL129986A0 (pt)
NO (1) NO326140B1 (pt)
OA (1) OA11057A (pt)
PL (1) PL191624B1 (pt)
SK (1) SK287687B6 (pt)
WO (1) WO1998024888A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
DE948609T1 (de) * 1996-12-06 2000-03-09 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
US7692067B2 (en) * 2002-09-18 2010-04-06 Mendel Biotechnology, Inc. Yield and stress tolerance in transgenic plants
NZ531180A (en) * 1999-03-26 2005-06-24 Aventis Pharma Inc Compositions and methods for effecting the levels of cholesterol using the LIPG polypeptide
GB9920334D0 (en) 1999-08-28 1999-11-03 Glaxo Group Ltd Method
US6337187B1 (en) 1999-11-05 2002-01-08 Millennium Pharmaceuticals, Inc. 18891, a novel human lipase
WO2001032885A2 (en) * 1999-11-05 2001-05-10 Millennium Pharmaceuticals, Inc. Human lipase
US20030165845A1 (en) * 2000-09-25 2003-09-04 Millennium Pharmaceuticals, Inc. 47647, a novel human lipase and uses therefor
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
CN102250854B (zh) * 2011-07-01 2013-03-27 浙江商达环保有限公司 用于处理油脂污染物的脂肪酶、编码基因及其应用
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
TWI688575B (zh) * 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 阻礙血管內皮脂酶之酵素活性的人類化單株抗體

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691181A (en) * 1984-08-21 1997-11-25 Celltech Limited DNA encoding lipase from human gastric mucosal tissue
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5364777A (en) 1992-04-03 1994-11-15 American Air Liquide Method of improving lipase activity using noble gases
US5616483A (en) * 1992-06-11 1997-04-01 Aktiebolaget Astra Genomic DNA sequences encoding human BSSL/CEL
DK88892D0 (da) 1992-07-06 1992-07-06 Novo Nordisk As Forbindelse
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
US5998189A (en) * 1992-12-16 1999-12-07 Warner-Lambert Company Polypeptide derivatives of dog gastric lipase and pharmaceutical compositions containing same
ES2164699T3 (es) * 1993-03-05 2002-03-01 Univ Catholique Louvain Anticuerpo lo-cd2a y usos del mismo para inhibir la activacion y la proliferacion de las celulas t.
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
WO1995002697A1 (fr) 1993-07-13 1995-01-26 Rhone-Poulenc Rorer S.A. Vecteurs adenoviraux defectifs et utilisation en therapie genique
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
EP0746618B1 (en) 1994-02-22 2002-08-21 Novozymes A/S A method of preparing a variant of a lipolytic enzyme
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
ES2236738T3 (es) 1995-05-31 2005-07-16 Medzyme N.V. Composicion para mejorar la digestibilidad y la utilizacion de nutrientes.
DE948609T1 (de) * 1996-12-06 2000-03-09 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Von humanem lipase-ähnlichem gen kodierte polypeptide, sowie zusammensetzungen und methoden
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
AU1941899A (en) 1997-12-19 1999-07-12 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use
US6337187B1 (en) * 1999-11-05 2002-01-08 Millennium Pharmaceuticals, Inc. 18891, a novel human lipase
US6558936B1 (en) * 1999-10-01 2003-05-06 Millennium Pharmaceuticals, Inc. Human lipase proteins, nucleic acids encoding them, and uses of both of these

Also Published As

Publication number Publication date
ES2239367T3 (es) 2005-09-16
OA11057A (en) 2002-03-08
EP0948609B1 (en) 2005-03-16
CN1167793C (zh) 2004-09-22
US20120114660A1 (en) 2012-05-10
JP4615634B2 (ja) 2011-01-19
US20030108538A1 (en) 2003-06-12
CZ299055B6 (cs) 2008-04-09
IL129986A (en) 2006-07-05
US8343494B2 (en) 2013-01-01
CN1539849A (zh) 2004-10-27
EP0948609A2 (en) 1999-10-13
NO326140B1 (no) 2008-10-06
US20070101451A1 (en) 2007-05-03
NO992735L (no) 1999-08-05
IL129986A0 (en) 2000-02-29
CA2273823C (en) 2007-06-05
US6395530B1 (en) 2002-05-28
WO1998024888A3 (en) 1998-08-13
HK1024929A1 (en) 2000-10-27
BG64798B1 (bg) 2006-04-28
DE948609T1 (de) 2000-03-09
KR20000069336A (ko) 2000-11-25
JP2010284171A (ja) 2010-12-24
BG103472A (en) 2001-01-31
AP1313A (en) 2004-10-04
CN100497610C (zh) 2009-06-10
PL191624B1 (pl) 2006-06-30
DE69732789D1 (de) 2005-04-21
AP9901548A0 (en) 1999-06-30
KR100516561B1 (ko) 2005-09-22
CN1240000A (zh) 1999-12-29
NO992735D0 (no) 1999-06-04
EA003293B1 (ru) 2003-04-24
CZ9902003A3 (cs) 2000-10-11
DE69732789T2 (de) 2005-08-11
HK1068636A1 (en) 2005-04-29
SK75399A3 (en) 2001-02-12
SK287687B6 (sk) 2011-06-06
JP5416053B2 (ja) 2014-02-12
WO1998024888A2 (en) 1998-06-11
AU5690598A (en) 1998-06-29
US7579447B2 (en) 2009-08-25
CA2273823A1 (en) 1998-06-11
EA199900522A1 (ru) 2000-02-28
ATE291080T1 (de) 2005-04-15
US7056720B2 (en) 2006-06-06
AU750891B2 (en) 2002-08-01
JP2001505769A (ja) 2001-05-08

Similar Documents

Publication Publication Date Title
Suchanek et al. Translation of melittin messenger RNA in vitro yields a product terminating with glutaminylglycine rather than with glutaminamide.
BR9713847A (pt) Polipeptìdeo isolado codificado por um gene semelhante a lipase, composição, composição farmacêutica, fragmento antigênico, ácido nucleico isolado, vetor, célula recombinante, anticorpo, célula de hibridoma, processos para preparar um polipeptìdeo, para triar agonistas ou antagonistas de atividade llg, para a hidrólise enzimática de um éster de fosfatidilcolina, e para melhorar o perfil de lipìdeo no soro de um humano ou outro animal tendo um perfil de lipìdeo indesejável, e, camundongo transgênico.
Vaandrager et al. Guanylyl cyclase C is an N-linked glycoprotein receptor that accounts for multiple heat-stable enterotoxin-binding proteins in the intestine.
Chandrasekhar et al. Induction of interleukin‐1 receptors on chondrocytes by fibroblast growth factor: a possible mechanism for modulation of interleukin‐1 activity
McDevitt et al. Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans
DK0758383T3 (da) Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
Dicou et al. Synthesis of nerve growth factor mRNA and precursor protein in the thyroid and parathyroid glands of the rat.
DE69532760D1 (de) Mittel zur verabreichung von antigenen
Markelonis et al. Sciatin is a transferrin‐like polypeptide
KR900700116A (ko) 뼈-유도 단백질
ATE426024T1 (de) C-c chemokin rezeptor 3: ckr-3 oder eos-l2
ATE63138T1 (de) Komplementaere polypeptide gegen peptide oder proteine mit mindestens teilweise bekannter aminosaeure- oder nukleotidkodierender sequenz und diesbezuegliches aufbauverfahren.
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
Chizzonite et al. Comparison of myosin heavy chains in atria and ventricles from hyperthyroid, hypothyroid, and euthyroid rabbits.
Garcia et al. An evolutionarily conserved enzyme degrades transforming growth factor-alpha as well as insulin.
SHOOTER et al. Biosynthesis and mechanism of action of nerve growth factor
Michalak et al. Identification and immunolocalization of calreticulin in pancreatic cells: no evidence for “calciosomes”
Mahuran et al. Evidence for two dissimilar polypeptide chains in the beta 2 subunit of hexosaminidase.
Planck et al. Intracellular processing of epidermal growth factor. II. Intracellular cleavage of the COOH-terminal region of 125I-epidermal growth factor.
Sternby et al. Evolutionary studies on pancreatic colipase
Sayari et al. Characterization of turkey pancreatic lipase
BR0016129A (pt) Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto
Levine et al. A recombinant rat regenerating protein is mitogenic to pancreatic derived cells
BR9507426A (pt) Composição de inibina e processos para uso das mesmas
Bollengier et al. Localization of the novel neuropolypeptide h3 in subsets of tissues from different species

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B25D Requested change of name of applicant approved
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE: NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96); NAO APRESENTA SUFICIENCIA DESCRITIVA (ART. 24 DA LPI); AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI); NAO E CONSIDERADO INVENCAO, UMA VEZ QUE INCIDE NO ART. 10 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 18A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.